曲罗芦单抗用于治疗成人中重度特应性皮炎
Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults.
作者信息
Abduelmula Abrahim, Rankin Brian D, Mufti Asfandyar, Yeung Jensen, Prajapati Vimal H
机构信息
Faculty of Medicine, University of Western Ontario, London, ON, Canada.
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
出版信息
Skin Therapy Lett. 2023 Jan;28(1):1-6.
Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.
特应性皮炎（AD）是一种常见的、慢性的、复发性的、免疫介导的炎症性皮肤病。靶向治疗选择仍然有限。曲罗芦单抗（Adtralza®）是一种有前景的新型全身治疗药物，可抑制白细胞介素-13。它最近获得了加拿大卫生部和美国食品药品监督管理局的批准，用于治疗成人中重度AD，可单独使用或与外用糖皮质激素联合使用。在此，我们回顾了曲罗芦单抗在成人中的疗效和安全性，这些疗效和安全性已在临床试验中得到证实。
Zotero 插件